FDA grants fast track designation to CNS pharmaceuticals for berubicin; an anthracycline for the treatment of recurrent glioblastoma multiforme (brain cancer)

Anthracyclines are designed to induce DNA damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer appeared to show positive response in a Phase 1 human CT.

Source:

Biospace Inc.